KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Inventory (2016 - 2025)

Historic Inventory for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $356.3 million.

  • Emergent BioSolutions' Inventory rose 1041.21% to $356.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.3 million, marking a year-over-year increase of 1041.21%. This contributed to the annual value of $311.7 million for FY2024, which is 522.96% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Inventory of $356.3 million as of Q3 2025, which was up 1041.21% from $338.6 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Inventory ranged from a high of $528.2 million in Q3 2022 and a low of $311.7 million during Q4 2024
  • In the last 5 years, Emergent BioSolutions' Inventory had a median value of $354.1 million in 2023 and averaged $363.5 million.
  • In the last 5 years, Emergent BioSolutions' Inventory soared by 6384.52% in 2021 and then crashed by 3296.1% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Inventory (Quarter) stood at $344.5 million in 2021, then grew by 1.8% to $350.7 million in 2022, then fell by 6.22% to $328.9 million in 2023, then dropped by 5.23% to $311.7 million in 2024, then rose by 14.31% to $356.3 million in 2025.
  • Its last three reported values are $356.3 million in Q3 2025, $338.6 million for Q2 2025, and $314.0 million during Q1 2025.